Synthesis of Iridium Nanoparticles

Summary

Technology Description

 

This technology licensing and collaborative research opportunity relates to simple aqueous synthetic methods that produce uncapped stable colloidal iridium nanoparticles (IrNPs). The synthesized IrNPs are highly crystalline as observed by X-ray diffraction and high resolution TEM imaging. In vitro metabolic toxicity assays using hepatocyte and macrophage cells demonstrate that both the synthesized IrNPs are well tolerated.

 

Features & Benefits

 

  • Simple aqueous synthetic methods that produce uncapped stable colloidal iridium nanoparticles
  • Synthesized IrNPs are non-toxic at concentrations at up to 50 μM iridium in hepatocytes, and stimulate metabolic viability in macrophage cells
  • Synthesis method is surfactant free

 

Applications

 

  • Synthesis of Iridium nanoparticles
  • Radiation dose enhancing Iridium nanoparticle development

 

Background of Invention

 

Noble metal nanoparticles are a mainstay of emerging nanotechnologies, due to their interesting optical, electronic and surface catalytic properties. In nanomedicine, these unique biomaterials have drawn significant attention due the ability to tailor their biological interactions through surface modifications for a wide range of applications. Iridium is used in a variety of applications (catalytic), including as a high density radiation dose enhancing nanoparticle for cancer therapy. 

 

Status

 

Patent pending 

 

Patent Information:
Tech ID:
OSU-17-26
Contact:
Joe Christison
IP & Licensing Manager
Oregon State University
541-737-9016
joe.christison@oregonstate.edu
Inventors:
Conroy Sun
Anna Brown
Gaurav Sahay
Keywords:
Iridium
Nanoparticles
Synthesis
© 2018. All Rights Reserved. Powered by Inteum